{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T15:40:11Z","timestamp":1793979611118,"version":"4.8.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"am","delay-in-days":283,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1\u202fU10 CA180822"],"award-info":[{"award-number":["1\u202fU10 CA180822"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ygyno.2024.03.027","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T16:38:40Z","timestamp":1712767120000},"page":"61-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016"],"prefix":"10.1016","volume":"186","author":[{"given":"Lilian T.","family":"Gien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Enserro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Waggoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda R.","family":"Duska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E.","family":"Wahner-Hendrickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Premal H.","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor","family":"Backes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kidd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn Y.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"DiSilvestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Covens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2024.03.027_bb0005","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ygyno.2011.01.005","article-title":"Clear cell carcinoma of the ovary: a report from the first ovarian clear cell symposium","volume":"121","author":"Anglesio","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.027_bb0010","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1525-1438.2007.01158.x","article-title":"Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan clear cell carcinoma study","volume":"18","author":"Takano","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.03.027_bb0015","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: interim results from the phase II KEYNOTE- 100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.027_bb0020","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.03.027_bb0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2024.03.027_bb0030","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.027_bb0035","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbrc.2005.09.032","article-title":"Biochemical and medical aspects of indoleamine 2,3-dioxygenase-initiated I-tryptophan metabolism","volume":"338","author":"Takikawa","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ygyno.2024.03.027_bb0040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2009.07.015","article-title":"Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma","volume":"115","author":"Inaba","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2024.03.027_bb0045","doi-asserted-by":"crossref","first-page":"O7","DOI":"10.1186\/2051-1426-3-S2-O7","article-title":"Preliminary results from a phase I\/II study of epacadostat (INCB024360) in combination with pembrolizumab in patients with selected advanced cancers","volume":"3","author":"Gangadhar","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ygyno.2024.03.027_bb0050","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/(SICI)1097-0258(19981030)17:20<2301::AID-SIM927>3.0.CO;2-X","article-title":"Optimal flexible designs in phase II clinical trials","volume":"17","author":"Chen","year":"1998","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2024.03.027_bb0055","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"issue":"Suppl. 7","key":"10.1016\/j.ygyno.2024.03.027_bb0060","doi-asserted-by":"crossref","first-page":"S783","DOI":"10.1016\/j.annonc.2022.07.649","article-title":"Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): phase II PEACOCC trial","volume":"33","author":"Kristeleit","year":"2022","journal-title":"Ann. Oncol."},{"issue":"16 suppl","key":"10.1016\/j.ygyno.2024.03.027_bb0065","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1200\/JCO.2022.40.16_suppl.5565","article-title":"A multicenter phase II randomized trial of durvalumab (D) versus physician\u2019s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA\/APGOT-OV2\/GCGS-OV3)","volume":"40","author":"Tan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.027_bb0070","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1136\/ijgc-2022-003430","article-title":"Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series","volume":"32","author":"Sia","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.03.027_bb0075","series-title":"Preliminary Results of Sintilimab (sin)+bevacizumab (Bev) in Recurrent\/Persistent Ovarian Clear Cell Carcinoma (INOVA): A Multicenter, Single-Arm, Phase II Trial","author":"Liu","year":"2022"},{"key":"10.1016\/j.ygyno.2024.03.027_bb0080","article-title":"Sintilimab combined with bevacizumab in relapsed\/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial\u2014a study protocol of clinical trial","volume":"12","author":"Li","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ygyno.2024.03.027_bb0085","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.2018.78.9602","article-title":"Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I\/II trial (ECHO-202\/KEYNOTE037)","volume":"36","author":"Mitchell","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.027_bb0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1146\/annurev-cancerbio-030419-033635","article-title":"Is there a clinical future for IDO1 inhibitors after the failure of epacadostat in melanoma?","volume":"4","author":"Van den Eynde","year":"2020","journal-title":"Ann Rev Cancer Biol"},{"key":"10.1016\/j.ygyno.2024.03.027_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy","volume":"110","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ygyno.2024.03.027_bb0100","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2024.03.027_bb0105","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","article-title":"ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade","volume":"24","author":"Shen","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2024.03.027_bb0110","article-title":"ARID1A mutations are associated with increased immune activity in gastrointestinal cancer","volume":"8","author":"Li","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ygyno.2024.03.027_bb0115","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ygyno.2021.07.005","article-title":"ARID1A mutation\/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer","volume":"162","author":"Kuroda","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2024.03.027_bb0120","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1136\/ijgc-2021-002973","article-title":"ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT\/GYN1\/NCRI)","volume":"31","author":"Banerjee","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2024.03.027_bb0125","author":"Prisma"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824001835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T21:59:47Z","timestamp":1727819987000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824001835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":25,"alternative-id":["S0090825824001835"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.03.027","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}